Arrowhead Pharmaceuticals Inc

Tema ETF Trust
Tema Cardiovascular and Metabolic ETF
Schedule of Investments
November 30, 2023 (Unaudited)

Investments	Number of Shares		Value
COMMON STOCKS - 98.1%
Biotechnology - 49.1%
Akero Therapeutics, Inc.*		6,204	$	103,855
Alnylam Pharmaceuticals, Inc.*		2,303		387,480
Amgen, Inc.		2,162		582,962
Arcturus Therapeutics Holdings, Inc.*		6,675		159,800
Arrowhead Pharmaceuticals, Inc.*		9,024		191,309
Ascendis Pharma A/S - ADR*^		2,914		292,653
Bridgebio Pharma, Inc.*		14,101		404,840
Crinetics Pharmaceuticals, Inc.*		10,387		330,203
Cytokinetics, Inc.*		5,499		184,107
Intellia Therapeutics, Inc.*		12,832		380,212
Ionis Pharmaceuticals, Inc.*		6,862		339,463
Madrigal Pharmaceuticals, Inc.*		1,458		296,411
Mereo Biopharma Group plc - ADR*^		122,952		256,970
Mineralys Therapeutics, Inc.*		18,471		123,017
Mirum Pharmaceuticals, Inc.*		5,734		183,889
Rocket Pharmaceuticals, Inc.*		15,040		350,883
Tenaya Therapeutics, Inc.*		47,893		90,039
Ultragenyx Pharmaceutical, Inc.*		8,319		323,193
Vertex Pharmaceuticals, Inc.*		1,739		617,015
Verve Therapeutics, Inc.*		10,623		119,827
Viking Therapeutics, Inc.*		15,652		191,267
Zealand Pharma A/S*^		5,076		249,032
				6,158,427
Health Care Equipment & Supplies - 22.8%
Boston Scientific Corp.*		5,452		304,712
Dexcom, Inc.*		4,372		505,053
Edwards Lifesciences Corp.*		4,982		337,331
Inari Medical, Inc.*		4,700		280,543
Insulet Corp.*		1,928		364,566
Masimo Corp.*		2,303		215,929
Medtronic plc - ADR ^		5,264		417,277
Omnicell, Inc.*		6,674		222,645
Shockwave Medical, Inc.*		1,222		213,300
				2,861,356
Insurance - 1.2%
Oscar Health, Inc., Class A *		17,249		146,617
Life Sciences Tools & Services - 2.1%
West Pharmaceutical Services, Inc.		753		264,122
Pharmaceuticals - 22.9%
Bayer AG^		6,956		237,444
Bristol-Myers Squibb Co.		5,828		287,787
Chugai Pharmaceutical Co., Ltd.^		12,267		431,736
Cymabay Therapeutics, Inc.*		11,703		223,878
Eli Lilly & Co.		1,034		611,135
Novartis AG^		3,713		360,912
Novo Nordisk A/S, Class B^		6,157		625,261
Structure Therapeutics, Inc. - ADR*^		1,598		88,993
				2,867,146
TOTAL COMMON STOCKS (Cost $12,262,446)				12,297,668

SHORT-TERM INVESTMENTS - 0.4%
Money Market Funds
First American Treausry Obligations Fund - Class X, 5.277% (a)		49,876		49,876
TOTAL MONEY MARKET FUNDS (Cost $49,876)				49,876

TOTAL INVESTMENTS (Cost $12,312,322) - 98.5%				12,347,544
OTHER ASSETS LESS LIABILITIES - 1.5%				187,497
NET ASSETS - 100.0%			$	12,535,041

* Non-income producing security.
^ Foreign security.
(a) 7-day net yield.
ADR - American Depositary Receipt
plc - Public Limited Company

The Global Industry Classification Standard (GICS^®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.

Tema Cardiovascular and Metabolic ETF
November 30, 2023 (Unaudited)
ALLOCATION BY SECTOR

Sector	Percentage of Total Net Assets
Health Care	96.9%
Financials	1.2%
Money Market Fund and Other Assets and Liabilities	1.9%
Total	100.0%

ALLOCATION BY COUNTRY

Country	Percentage of Total Net Assets
United States	74.9%
Denmark	9.3%
Japan	3.4%
Ireland	3.3%
Switzerland	2.9%
United Kingdom	2.1%
Germany	1.9%
Cayman Islands	0.7%
Other⁽¹⁾	1.5%
Total	100.0%

⁽¹⁾Includes cash and net other assets (liabilities).

Tema ETF Trust
Tema Cardiovascular and Metabolic ETF
Notes to Quarterly Schedule of Investments
November 30, 2023 (Unaudited)

Investment Valuation
The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's’ own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

• Level 1 — Quoted prices in active markets for identical assets that the Fund's have the ability to access.
• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
• Level 3 — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of November 30, 2023:

Tema Cardiovascular and Metabolic ETF	Level 1		Level 2		Level 3		Total
Investments
Common Stocks *	$	12,297,668	$	-	$	-	$	12,297,668
Money Market Fund		49,876		-		-		49,876
Total Investments	$	12,347,544	$	-	$	-	$	12,347,544

* See Schedule of Investments for segregation by industry.